Our latest deal : Domain Therapeutics raises $42M series A
French biotech company will use its bioSens-All proprietary technology to correlate impact of GPCR mutations on signaling pathways Results may
Paris, May 14, 2020 – The French company specialized in MedTech, PKvitality, is the first to be accelerated by Dassault
• Merck KGaA, Darmstadt, Germany’s decision to enter regulatory development with drug candidate triggers first development milestone • Candidate will
Paris, January 7th, 2020 – PKvitality, a French company specialized in bio wearables, has signed an agreement with Beurer GmBH,
Paris, December 04, 2019 – PKvitality, a French company specialized in bio wearables, was awarded first position in Medtech category
Paris, November 6th, 2019 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including
by Jean-Alexandre Kaminisky, 2021-03-16 MyPL wins €1.1 Million European Union grant as part of Horizon Europe 2020 GerOnTe[1] project out of a
A major step and a critical milestone achieved prior to First In Human clinical trials FineHeart’s TET is a system
– SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension
Latest Insights
French-Canadian biotech company has nominated DT-9081 as development candidate and launched CMC activities • DT-9081 will be combined with immune
– SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension
Paris, February 7th 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that
Overall demand totaling €14.7 million, 1.24 times the offering The funds raised will be used to implement the strategy of
This press release may not be published, forwarded or distributed, directly or indirectly in the United States of America, Canada,